Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Magnetic zaps to the spine could ease diabetic stomach troubles

NCT ID NCT05273788

Symptom relief Sponsor: Medical University of South Carolina Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Sep 15, 2026 · Updated 3 times

Summary

This early-stage trial tests a noninvasive device that uses magnetic pulses to stimulate nerves in the upper back. The goal is to reduce severe nausea, vomiting, and stomach pain in people with diabetic gastroparesis (stomach paralysis). About 48 adults with moderate-to-severe symptoms will receive either real or sham stimulation to see if it improves symptoms and quality of life.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
magnetic nerve stimulation device (ThorS-MagNT)
What this could lead to
If it works, this could offer a new, noninvasive way to reduce nausea, vomiting, and stomach pain in people with diabetic gastroparesis.
What could go wrong
This is a very early Phase 1 trial with only 48 people, so results may not apply to everyone. The device may not work better than a sham (fake) treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

36 people

The number who actually took part.

Started

Jul 2022

Finished

Jun 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 85 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Outpatient DGp patients with refractory symptoms and total ANMS GCSI-DD score ≥ 2.0 (moderate-severe severity) during screening period; 2. Men or women age less than 85; 3. No known mucosal disease; 4. Speak, write, and understand English (by self-report); 5. On stable doses of any medication for 30 days prior to entering the study (exceptions are psychotropic, opioids, and/or illicit drugs) and agrees not to change medications or dosages during the study period. Exclusion Criteria: 1. Postsurgical gastroparesis; 2. Gastrointestinal obstruction; 3. Prior gastric surgery (fundoplication, gastric resection or pyloroplasty); 4. Achalasia, Chronic Intestinal Pseudo-obstruction, Colonic Inertia with one complete spontaneous bowel movement (CSBM) less than every 2 weeks; 5. Active inflammatory bowel disease; 6. Use of opioids greater than 3 times a week and marijuana more than 5 times a week; 7. Change in neuromodulator dosage in last 3 months (tricyclic antidepressants, gabapentin, olanzapine, etc.); 8. Use of sympathomimetics; 9. Seizure history or disorder; 10. Active serious psychiatric illness that would warrant independent attention; 11. Severe, unstable cardiac disease and arrhythmias; 12. Metal implants that are not MR safe, gastric electrical stimulators (GES), deep brain stimulators (DBS), sacral nerve stimulators (SNS), or pacemakers; 13. Pregnant women or nursing mothers; 14. Enteral or parenteral feeding

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Diabetic gastroparesis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

gastroparesis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Diabetic gastroparesis

Contacts and locations

Locations

  • Augusta University

    Augusta, Georgia, 30912, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.